Ono Pharmaceutical Co., Ltd. / LigaChem Biosciences, Inc.
2024 · Licensing/Option · $700M · Pending
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.